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Early Identification of Neutropenic Patients at Risk o f Gram-
positive Bacteraemia and the Impact of Empirical
Administration of Vancomycin
E.C. Dompelingj1 J.P. Donnelly^1 S.C. Deresinski,2 R. Feld,3 E.F. Lane-Allman4 and 
B.E. De Pauw1 for The Intercontinental Antimicrobial Study Group*
division of Hematology, University Hospital St. Radboud3 P.O. Box 9101, 6500 HB Nijmegen, The 
Netherlands; 2Stanford University School of Medicine3 Palo Alto, California 94062, U.S.A; 3Princess Margaret 
Hospital, 500 Sherbourne Street, Toronto3 Ontario, Canada M4X 1K9; 4Glaxo Group Research Ltd, Greenford
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The aim of this multicentre randomised trial was to determine whether it was possible to predict gram- 
positive bacteraemia, and whether the empirical use of vancomycin would lead to reduced morbidity 
and mortality. 35 of 113 patients (31%; confidence interval. Cl 8.5), who presented with a skin or soft 
tissue infection and had received empirical vancomycin in addition to either ceftazidime or piperacil- 
lin-tobramycin, had initial bacteraemia with a single gram-positive bacterium compared with 135 of 
the 784 (17%; Cl 2.6), who presented with another infection and who had been given ceftazidime or 
piperacillin-tobramycin without vancomycin (P<0.G01). Empirical vancomycin resulted in a higher 
rate of eradication (P = 0.033, relative risk 1.2), but not a better clinical outcome and was associated 
with more toxicity (P=0.042, relative risk 1.6). Irrespective of the initial treatment regimen, fever 
lasted an average of 8 days, the empirical regimen was modified in more than 50% of cases and 
mortality attributed to gram-positive infection was less than 2%. Incorporating vancomycin in the 
initial empirical antibiotic regimen for febrile neutropenic patients does not appear necessary, even
for skin and soft tissue infections associated with gram-positive bacteraemia. Copyright © 1996 Elsevier 
Science Ltd
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INTRODUCTION
D u r i n g  t h e  1980s, gram-positive bacteria became increas­
ingly more conspicuous in causing infection in neutropenic 
patients with cancer [13 2]. Their increasing prominence is 
due to the greater use of indwelling intravenous catheters
[3], the severe mucositis that results from more intensive
Correspondence to E.C. Dompeling.
*For participating investigators and institutions we refer to: De Pauw 
BE, Deresinski SC, Feld R, Lane-Allmann EFj Donnelly JP. Ceftazid­
ime compared with piperacillin and tobramycin for the empirical 
treatment of fever in neutropenic patients with cancer, Ann Intern 
Med 1994,120, 834-844.
Received 14 Aug. 1995; revised 8  Jan. 1996; accepted 3 Feb. 1996. 
Preliminary data were presented at the 17th International Congress 
of Chemotherapy3 Berlin, June 19913 Abstract no. 1403.
chemotherapy and radiotherapy [4]3 and the widespread use 
of oral antibacterial prophylaxis which has reduced the inci­
dence of gram-negative infections [5]. Since there are no 
reliable clinical means of distinguishing between patients with 
fever due to a potentially life-threatening infection from those 
at lesser risk3 empirical antimicrobial regimens must provide 
adequate cover against gram-negative infections as these can 
prove rapidly fatal. Standard regimens consist of a (3-lactam 
either alone or in combination with an aminoglycoside, but 
these are deficient in their activity against many of the com­
mon gram-positive bacteria. The glycopeptides3 vancomycin 
and teicoplanin3 are the drugs of choice for resistant gram- 
positive bacteria, particularly the coagulase-negative staphylo­
co cci3 most of which are resistant to methicillin. While there 
is a general consensus that these drugs constitute an essential
1332
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part of the empirical regimen in centres where methicillin 
resistant Staphylococcus aureus are endemic, it is unclear 
whether specific anti-gram-positive therapy should always be 
included initially to complement the empirical regimen, given 
the less aggressive nature of most gram-positive infections.
Gram-positive bacteraemia accompanies approximately 
20% of episodes of first fever [2, 6, 7] but, in their retrospec­
tive analysis, Rubin and colleagues observed that treatment 
with vancomycin was required in only 57% of these [8]. 
Therefore, at least 80% of febrile neutropenic patients could 
be overtreated with a glycopeptide antibiotic when such ther­
apy is given routinely initially^ leading to unnecessary costs, 
increased risk of toxicity and the potential for the development 
of antibiotic resistance [9, 10], Patients at high risk of gram- 
positive infection may be those most likely to benefit from the 
empirical addition of a glycopeptide, but it is questionable 
whether they can be identified at the onset of fever. Based on 
our previous experience [11], we hypothesised that these were 
likely to be patients with skin and soft tissue infection such as 
cellulitis, catheter-related infections and other skin lesions, 
and so they were given vancomycin in addition to the core 
regimen of ceftazidime or piperacillin and tobramycin as part 
of a large multicentre randomised trial of the empirical treat­
ment of fever in neutropenic patients with cancer [12]. This 
allowed us to determine whether is was possible to predict 
gram-positive bacteraemia and see whether or not the 
inclusion of vancomycin would lead to a decrease in morbidity 
and mortality.
PATIENTS AND METHODS
Study design, patient inclusion and management
From 1988 to 1989, 35 centres in Europe, Canada, the 
United States of America, Asia and Australia participated in a 
non-blinded, randomised study of the management of fever in 
neutropenic cancer patients. Patients older than 12 years were 
eligible for inclusion when febrile with a single temperature of 
38.5°C or had at least two readings of >38°C taken 2 h apart, 
and neutropenic with a granulocyte count <500 cells/mm3 or 
one that was expected to fall to this level during the next 3 days 
following intensive chemotherapy for leukaemia, lymphoma or 
other malignancies or after bone marrow transplantation. 
Patients who had received previous parenteral antibiotic ther­
apy during the same neutropenic episode were excluded, as 
were those who were allergic to any of the trial antibiotics, 
whose creatinine exceeded 265 jxmol/1 or who only received 
palliative treatment for their underlying disease. All prophylac­
tic antibacterial agents were stopped at the onset of fever, 
except for tubérculostatics and prophylaxis against Pneumo­
cystis carinii infection with sulphamethoxazole-trimethoprim 
administered twice weekly. Patients were evaluated clinically 
before randomisation and during follow-up as previously 
described [12], and at least 10 ml of blood drawn from two 
separate venepunctures were also obtained for culture, with 
another 10 ml being drawn from a central venous catheter 
when present.
Informed consent was obtained from patients or their par­
ents or guardians. The protocol was approved by the ethics 
committees of the participating institutions.
Study population
879 neutropenic patients were enrolled, with 1086 episodes 
of fever. Patients had been stratified into those presenting with 
suspected abdominal anaerobic infections or skin or soft tissue
infections likely to be due to gram-positive bacteria, and those 
who presented with other infections who comprised the main 
group. One hundred and eighteen episodes had to be excluded 
because of protocol violations. In addition, the 71 episodes of 
presumed anaerobic infection were excluded from the present 
analysis leaving 897 assessable episodes.
Skin or soft tissue infections were apparent at the onset of 
113 episodes of fever (12 .6%), and, therefore, vancomycin 
was administered together with ceftazidime as empirical ther­
apy in 61 cases and with the combination of piperacillin and 
tobramycin in the remainder. Of the 784 remaining episodes, 
ceftazidime was given alone in 389 episodes and piperacillin 
plus tobramycin was given to the rest. Treatment was discon­
tinued once all signs and symptoms of infection had resolved 
for at least 2 consecutive days after the granulocyte count had 
risen to > 5 00/mm3 or for at least 5 days when neutropenia 
persisted.
Vancomycin treatment
One gram of vancomycin was given every 12 h. The proto­
col allowed for the later addition of vancomycin to ceftazidime 
or the combination when a clinically significant gram-positive 
organism was resistant to the initial empirical regimen, or 
persisted after at least 48 h of therapy, or when clinical deterio­
ration occurred in the setting of presumed or proven gram- 
positive bacteraemia. The reason for adding vancomycin and 
for making all other modifications to study therapy was 
recorded in the case record form.
Microbiology
Bacteraemia was defined by the occurrence of similar strains 
of coagulase-negative staphylococci or skin coryneforms in 
two blood cultures or a single positive culture of any other 
organism. Antimicrobial susceptibility was determined by agar 
diffusion, and zones of inhibition of less than 18 mm in 
diameter indicated resistance to ceftazidime and piperacillin, 
and zones of less than 15 mm to tobramycin. A strain was 
considered resistant to die combination when resistant to 
both piperacillin and tobramycin. Methicillin resistance was 
determined according to local practice.
Assessment of efficacy
Defervescence was considered to have occurred when the 
temperature had returned to below 37,5°C for at least 2 days.
The clinical outcome was evaluated at the end of treatment 
according to the criteria previously reported [12]. If treatment 
had to be discontinued for reasons unrelated to infection, e.g. 
a non-infectious death, a case was considered ‘not assessable’. 
Treatment leading to complete resolution of signs and symp­
toms of infection was considered a ‘success without modifi­
cation3, unless other agents were given together with the 
empirical regimen, when empirical therapy was deemed a 
‘success with modification’. Only death attributable to any 
infection, whether primary or subsequent, was regarded as 
‘treatment failure3.
Eradication was defined as the absence of the original 
pathogen(s) from blood cultures taken during treatment. 
Recovery of the original pathogen after treatment was 
regarded as relapse. Isolation of a new pathogen from any 
clinical site of infection during treatment was considered 
a superinfection and a new infection when it was isolated 
after treatment.
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Assessment of toxicity
All patients were assessed for toxicity and all adverse events 
were assessed for their relation to the study treatment by the 
investigator. A skin rash was considered evidence of an allergic 
reaction when it was temporally related to antimicrobial ther­
apy. Nephrotoxicity was defined as an increase of at least 
50% in the baseline concentrations of serum creatinine, and 
hepatotoxicity as a 2-fold or greater increase in baseline con­
centrations of bilirubin, serum transaminases or alkaline phos­
phatase.
Statistics
All means are presented with their 95% confidence intervals 
(Cl). Comparison of means was made using analysis of vari­
ance and categorical data were analysed by means of the 
X2-test.
The effect of adding vancomycin to the empirical regimen 
on clinical outcome* eradication, toxicity and the emergence 
of subsequent infections was evaluated using the Mantel- 
Haenszel test after taking the confounding factor of each 
empirical regimen into account and the data were expressed 
as a relative risk.
RESULTS
Patient demography 
The four treatment groups were similar in terms of age, sex, 
underlying disease, the proportion of patients given a bone 
marrow transplant and the degree and duration of neutropenia 
(Table 1). The majority of patients in all the treatment groups 
were managed with a central venous access device.
Gram-positive infections 
Bacteraemia due to a single gram-positive organism 
occurred in 170 of the 897 (19%) of the first febrile episodes 
during neutropenia (Table 2). A higher proportion of patients 
allocated to receive vancomycin from the beginning had mon- 
omicrobial gram-positive bacteraemia (35 of 113, 31%; Cl 
8.5) than did those given the other regimen alone (135 of 784, 
17%; Cl 2.6, P< 0.001). Polymicrobial bacteraemia involving 
gram-positive bacteria occurred twice as often amongst pati­
ents given vancomycin from the start. Coagulase-negative 
staphylococci, both alone and together with other bacteria, 
were isolated from the blood more frequently in patients that 
received the vancomycin-containing empirical regimens (28 of 
113, 25%) than in the remainder (79 of 784, 10%; P<0.001).
Unfortunately, data on susceptibility testing in primary 
monomicrobial gram-positive bacteraemia were incomplete. 
Forty-one of 79 isolates of coagulase-negative staphylococci 
were tested for the susceptibility to the empirical regimens of 
which 20 (49%) were susceptible. Of the 63 isolates of coagul­
ase-negative staphylococci tested for susceptibility to methicil­
lin, 38 (60%) were resistant. Details are provided in Table 3. 
Of 12 of the 17 isolates of Staphylococcus aureus tested, all were 
susceptible to the initial regimen and resistance to methicillin 
was found once in 10 strains tested* Susceptibility to the 
empirical regimen was demonstrated in 97% of the viridans 
streptococci and 73% of other gram-positive organisms that 
were tested.
Overall clinical outcome 
Infectious mortality in all treatment groups was similar 
(Table 4).
3 patients treated initially with ceftazidime alone (0,8%)
and 6 given piperacillin and tobramycin alone (1.7%) died 
due to gram-positive infection, both primary and subsequent. 
One patient initially treated with piperacillin and tobramycin 
in combination with vancomycin for gram-positive infection 
died. Details of the fatal gram-positive infections are summar­
ised in Table 5. Only 2 patients died of gram-positive infection 
within the first 7 2 h of empirical treatment.
Six of the deaths occurring in the ceftazidime group were 
caused by other bacterial infections, six by fungal infections, 
and one each by a viral and a Pneumocystis carinii infection. 
The deaths of patients treated with piperacillin and tobramy­
cin as the empirical regimen were attributed to other bacteria 
in 6 cases, fungi in 7, virus in 1, both a fungus and a virus in 1 
and to Pneumocystis carinii in 2 cases. The cause of death was 
thought to have been infectious although the cause was not 
determined in 4 patients treated with ceftazidime and in 6 
patients treated with piperacillin and tobramycin. One of 
the patients treated with ceftazidime in combination with 
vancomycin died due to a fungal infection and 2 of presumed 
infection. 2 patients treated with piperacillin-tobramycin in 
combination with vancomycin also died, presumably due to 
infection.
The time to defervescence was similar for all four treatment 
groups and the initial antibiotic regimen was modified in the 
majority of cases (Table 4). However, the first modification 
was made significantly later in the treatment groups in which 
vancomycin was incorporated in the empirical regimen. Van­
comycin was added to the empirical regimen of ceftazidime as 
first modification in 28% and as a later modification in 15% 
of cases and to the combination of piperacillin and tobramycin 
in 33% and 13%, respectively. The average number of antimi­
crobial agents eventually added to each of the four regimens 
was not different* Treatment was stopped in approximately 
25% of patients while they were still neutropenic and, in the 
remainder, when neutropenia had resolved.
Clinical outcome of primary gram-positive bacteraemia
In the subgroup of patients who had a monomicrobial 
gram-positive bacteraemia at the time of randomisation, the 
proportion of episodes responding to the initial regimen with­
out modification was similar in the four treatment groups, 
whether or not vancomycin was given empirically. Modifi­
cation was deemed necessary in 33 of 56 (59%) assessable 
episodes treated with ceftazidime alone, 50 of 73 (68%) of 
episodes treated with piperacillin and tobramycin alone, and 
in 11 of 18 (61%) and 8 of 14 (57%) episodes treated 
empirically with ceftazidime and vancomycin, or piperacillin- 
tobramycin and vancomycin, respectively. Treatment failure, 
not only due to the primary gram-positive infection but also 
attributable to other micro-organisms causing subsequent 
infections, occurred in 3 of 56 (5%) and 8 of 73 (11%) of 
patients not treated empirically with vancomycin and, due to 
presumed infection, in 1 of 18 (6%) and in 1 of 14 (7%) when 
the glycopeptide had been incorporated in the initial regimen, 
together with ceftazidime or piperacillin and tobramycin, 
respectively.
MicrobiologicaI outcome
Overall, eradication of bacteraemia was achieved in 72 of 
91 (79%) assessable cases treated with ceftazidime alone 
and in 73 of 107 (68%) cases treated with piperacillin and 
tobramycin alone. The incorporation of vancomycin in the 
initial empirical regimens resulted in significantly higher eradi-
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Tabla 1. Demographic and clinical characteristics
No empirical vancomycin Empirical vancomycin
(n = 784) ( » * 1 1 3 )
Ceftazidime Piperacillin-tobramycin Ceftazidime Piperacillin-tobramycin
(« = 389) (n =  395) (n =  61) ( « - 5 2 )
Age, years, mean (Cl) 44.5 (1.7) 45,4 (1.8) 43.9 (4.5) 42.0 (4.7)
Sex, % males 58 52 57 46
Underlying disease
Acute leukaemia, % 70 6 6 70 77
Bone marrow transplant, % 16 14 1 1 13
Central venous line, % 69 71 87 87
Granulocyte count at entry, % (n ~ 284) {n = 282) (n ~* 42) in -= 38)
< 1 0 0 /mm3 6 8 67 67 6 6
100-500/mm3 2 1 18 24 8
>500/mm3 1 1 15 1 0 26
Duration of neutropenia, days,
mean (Cl) < 500/mm3 17.9 (1.5) 18.0 (1.4) 20.0 (4.4) 19.1 (4.1)
< 1 0 0 /mm 3 13.4 (1.3) 12.7 (1,1) 14.9 (2.8) 15.7 (3.8)
Granulocyte count at study end, % (n = 323) {n = 321) (n =‘ 54) (n =: 42)
< 500/mm3 24 2 1 24 29
Oral antibacterial prophylaxis, n (%)
Fluoroquinolone 41 ( 1 1 ) 29 (7) 4 (7) 2 (4)
Co-trimoxazole 45 (1 2 ) 85 (2 2 ) 3 (5) 9 (17)
Other regimens 6 8 (17) 48 ( 1 2 ) 14 (23) 14 (27)
None 235 (60) 233 (59) 40 (6 6 ) 27 (52)
Bacteraemias, n (%) 124 (32) 138 (35) 30 (49) 25 (48)
Gram-positive 58 (15) 77 (19) 19 (31) 16 (31)
Gram-negative 45 ( 1 2 ) 32 (8 ) 3 (5) 7 (13)
Miscellaneous 3 (1 ) 5 ( 1 ) 0 (0 ) 0 (0 )
Polymicrobial 18 (5) 24 (6 ) 8 (13) 2 (4)
Other microbiologically documented
infections, n (%) 28 (7) 32 (8 ) 6 ( 1 0 ) 9 (17)
Clinically documented infections, n (%) 41 (1 1 ) 41 ( 1 0 ) 25 (41) 18 (35)
Unexplained fever, n (%) 196 (50) 184 (47)
Table 2. Episodes of initial gram-positive bacteraemia in relation to initial infection
Skin or soft tissue 
Other infections* infection
No empirical vancomycin Empirical vancomycin
(n = 784) (n = 1 1 3 )  P-value
Monomicrobial gram-positive bacteraemia 
Number of episodes, (%)f 
Number of strains, (%)j*
Coagulase-negative staphylococci 
Staphylococcus aureus 
Viridans streptococci 
Other gram-positive bacteria
Polymicrobial bacteraemia involving at least one gram-positive bacterium
Number of episodes, (%)t
Total no. of gram-positive strains:):
Coagulase-negative staphylococci 
Staphylococcus aureus 
Viridans steptococci 
Other gram-positive bacteria
135 (17) 35 (31) <0.001
57 (7) 22 (19)
13 (2) 4 (4)
48 (6 ) 8  (7)
17(2) 1(1)
36(5) 10(9) =0.09
55 15 
22 6 
2 0 
16 5 
15 4
*A11 episodes except skin or soft tissue infection. fPercentages of all episodes in the treatment group. ^Note the number of strains exceeds the 
number of episodes.
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Table 3. Susceptibility to the empirical regimen and to methicillin of 
79 isolates o f  co agulase-n egativ e staphylococci from monomicrobial
bacteraemia
Empirical regimen
Susceptible Resistant Not tested
Methicillin (iz = 2 0 ) (« = 2 1 ) (» =  38)
Susceptible (» = 25) 1 2 3 10
Resistant (» = 38) 2 16 2 0
Not tested (n = 1 6 ) 6 2  8
cation rates: 21 of 23 (91%) cases treated with vancomycin 
and ceftazidime and 17 of 18 (94%) cases with vancomycin 
in combination with piperacillin and tobramycin (P= 0.033, 
relative risk 1 .2).
Bacteriological clearance was not achieved by ceftazidime 
alone in 13 of 44 (30%) episodes involving a single gram- 
positive bacterium nor by piperacillin and tobramycin alone 
in 23 of 63 (37%) episodes. Bacterial persistence was encoun­
tered in 1 of 16 (6%) episodes of bacteraemia with a single 
gram-positive bacterium treated with vancomycin and ceftazi­
dime empirically, and in 1 of 10 (10%) episodes treated with 
vancomycin, piperacillin and tobramycin empirically 
(P=0.013, relative risk 1.4). Coagulas e-negative staphylococci 
persisted in 9 of 20 (45%) episodes treated with ceftazidime 
alone, and in 14 of 27 (52%) episodes treated with piperacillin 
and tobramycin. None of the coagulase-negative staphylococci 
persisted in patients receiving vancomycin-containing regi­
mens.
New bacteraemia caused by Entero coccus faecalis occurred 
once after discontinuing ceftazidime alone and by coagulase 
negative staphylococci twice after stopping piperacillin and 
tobramycin.
Table 4. Overall clinical outcome
Piperacillin- Ceftazidime and Piperaciilin-tobramycin
Ceftazidime alone tobramycin alone vancomycin and vancomycin
(« = 367)* (n = 355)* (» = 53)* (» = 45)*
Success, n (%) 127 (35) 117 (33) 2 2 (42) 19 (42)
Success with modification 219 (60) 209 (59) 28 (53) 23 (51)
Failure (infectious mortality) 2 1 (6 ) 29 (S) 3 (6 ) 3 (7)
Attributable to gram-positive infection 3 (0 .8 ) 6 (1.7) 0 (0 ) 1 (2 )
Days to no fever, mean (Cl) 7.6 (0 .8 ) 7.5 (0.7) 7.7 (2 .2 ) 8 . 0 (2 ,2 )
Days on study 17.0 ( 1 -1 ) 16.6 ( 1 .1 ) 18.3 (3.1) 18.3 (3.4)
Days to first modificationf 6.5 (0 .6 ) 5.9 (0.5) 8 . 8 (1.5) 9.3 (2-3)
Number of modifications 2.5 (0 .2 ) 2 . 6 (0 .2 ) 2.5 (0 .8 ) 1 . 8 (0.4)
^Number of assessable episodes. f P <  0.001 (analysis of variance).
Table 5. M ortality  attributable to gram-positive infections
Empirical regimen Organism
Susceptibility to 
empirical regimen
Susceptibility to 
methicillin
Attributable cause 
of death Day died*
Ceftazidime alone E. faecalis, 
C. freundii
Resistant n.t. Primary bacteraemia 2
C o agul as e-negative 
straphylococci
Resistant Resistant Primary bacteraemia 8
Enterococcus spp n.t.f n.t. Superinfection 7
Piperaciilin- S. aureus n.t. Resistant Primary bacteraemia 2
tobramycin alone Coagulase-negative
staphylococci
n.t. Susceptible
• »
Primary bacteraemia 4
viridans
streptococcus
Susceptible n.t. ARDS following 
primary bacteraemia
7
viridans
streptococcus
Susceptible n.t. ARDS following 
primary bacteraemia
8
5*. pneumoniae, 
Acinetobacter spp
Susceptible n.t. Primary bacteraemia 4
Lactobacillus spp n.t. n.t. Superinfection with 
bacteraemia and 
pneumonia
41
Piperaciilin- 
tobramycin and 
vancomycin
Saureus n.t. Resistant Superinfection with 
pneumonia
14
*Day after empirical therapy was begun. fN o t  tested. ARDS, acute respiratory distress syndrome.
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Adverse experiences
Superinfection rates were similar whether they initially 
received vancomycin as part of the empirical regimen 
(ceftazidime and vancomycin: 15%, piperacillin and tobramy­
cin and vancomycin: 8%) or not (ceftazidime alone: 10%, 
piperacillin and tobramycin alone: 10%). The number of 
gram-positive organisms cultured from the blood or lung 
during antimicrobial therapy was similar in all treatment 
groups; 19 isolates (ceftazidime alone), 10 (piperacillin and 
tobramycin alone), 3 (ceftazidime and vancomycin) and one 
(piperacillin, tobramycin and vancomycin).
4 patients treated with ceftazidime alone died of fungal 
superinfection as did 8 who had received piperacillin and 
tobramycin alone, and one who had been given ceftazidime 
and vancomycin empirically.
The empirical use of vancomycin was associated with added 
toxicity (Table 6) (P— 0.042, relative risk 1.6), but there 
were no statistically significant differences in the types of 
adverse events.
DISCUSSION
Within the context of a large multicentre trial of the 
management of febrile, neutropenic patients with parti­
cularly haematological malignancies, we were able to ident­
ify a group of patients with a skin or soft tissue infection 
who were twice as likely to have bacteraemia due to gram- 
positive bacteria, particularly the coagulase-negative sta­
phylococci, solely on the basis of their presenting clinical 
symptoms. This illustrates the fact that, even at the onset 
of fever, febrile neutropenic patients do not comprise a 
homogenous population. Microbiologically defined infec­
tion, including those accompanied by bacteraemia, clini­
cally defined infection and unexplained fever each account 
for approximately a third of febrile neutropenic episodes [2,
11]. The lower respiratory tract accounts for almost 60% of 
the cases presenting with clinically manifest infection at the 
onset of fever or later, skin and soft tissue lesions contribute 
almost 20% and the remainder are equally divided between 
the upper respiratory tract and other sites [13], Approxi­
mately 4%) of episodes without a focus of infection culmi­
nate in death in comparison with 2 1% of episodes in which 
a focus is identified. This difference can be explained by the 
high mortality rates associated with pulmonary infiltrates 
and the subsequent development of evident foci of infection
[13]. Also, after excluding urinary tract infection, the pres­
ence of an infectious focus is associated with a significantly 
longer duration of fever in response to which treatm ent is 
prolonged, resulting in more frequent modification of the 
empirical regimen [11]. Thus, patients with a clinically 
defined infection clearly represent a different population 
from those without any clinically identifiable infection 
focus. Moreover, certain sites of infection, such as those 
involving the skin or soft tissue may provide a clue to the 
causative organism, as was demonstrated in this study. 
Therefore, given the variety of factors including local cir­
cumstances, cultures results and clinical condition that are 
cited as a basis for individualising treatment, it seems sur­
prising that the presenting signs and symptoms of infection 
have been largely ignored especially as this might lead to a 
needless delay in selecting appropriate antimicrobial ther­
apy.
In the present study, patients presenting initially with a skin 
or soft tissue infection were assigned non-randomly to an 
empirical antibiotic regimen which included vancomycin. 
Those without a skin or soft tissue infection served as a control 
group for assessing the impact of adding the glycopeptide 
since they too developed gram-positive bacteraemia. Apart 
from the presenting focus of infection, the treatment groups 
were well balanced for demographic and clinical character­
istics. Gram-positive bacteria persisted in the bloodstream of 
patients treated empirically without vancomycin more often 
than in those given the drug from the start, yet the inclusion 
of the glycopeptide had little impact on the clinical outcome.
No patient given vancomycin empirically died as a result of 
primary bacteraemia with gram-positive bacteria but 7 of the 
patients treated with the empirical regimens that did not 
include the glycopeptide proved fatal due to primary bacterae­
mia and another 2 due to superinfections with gram-positive 
bacteria. Despite the fact that vancomycin was included in the 
initial regimen, 1 patient died from a gram-positive superinfec­
tion.
One patient given piperacillin and tobramycin without van­
comycin died of a primary infection with a methicillin-resist- 
ant Staphylococcus aureus. It is unlikely that this death could 
have been prevented, given the fact that it occurred within 
48 h of starting therapy. The virulence of methicillin-resistant 
Staphylococcus aureus was further demonstrated by the death of 
a patient who developed a superinfection due to this organism
Table 6. Toxicity
Piperacillin-
Piperacillin- Ceftazidime and tobramycin and
Ceftazidime alone tobramycin alone vancomycin vancomycin
(n =  389) (« =  395) {n = 61) (« = 52)
All patients with adverse events, n (%)* 30 (8 ) 
Adverse events
Allergyf 18 (5) 
Gastro-intestinal 1 (<  1 ) 
Hepatotoxicity 5 (1)
Nephrotoxicity^ 3 (1 )
Ototoxicity 0  (0)
78 (20) 11 (18) 12 (23)
37 (9) 8(13) 4(8)
5(1) 1 (2) 0(0)
3(1) 2(3) 0(0)
34 (9) 1 (2) 7 (13)
4(1) 0(0) 1 (2)
*P= 0.042. fP=0.143. :j:P=0.195 (Mantel-Haensze) test).
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despite having received empirical therapy with vancomycin.
2 patients died after developing acute respiratory distress 
syndrome following primary bacteraemia due to viridans 
streptococci despite being treated with piperacillin, a ureido- 
penicillin that is active in vitro against streptococci, although 
no follow-up cultures were taken to show the organism was 
eradicated. However, it is doubtful whether antibiotic therapy 
alone, even if it includes vancomycin, would have prevented 
this manifestation of sepsis syndrome since patients who 
develop acute respiratory distress syndrome following bacter­
aemia with viridans streptococci require adjunctive therapy 
with corticosteroids [14]. Moreover, giving high-dose cortico- 
steriods to complement the antimicrobial treatment of bac­
teraemia due to Streptococcus mitis may prove more effective in 
pre-empting the development of acute respiratory distress 
syndrome by suppressing the mechanisms that induce the 
syndrome [15], The death of 1 of the 2 patients treated 
without vancomycin who died as a result of superinfection 
with gram-positive bacteria may have been inevitable since 
lactobacilli were involved in this fatal case and the addition of 
vancomycin would have had little impact, since these bacteria 
are only marginally susceptible to the glycopeptides [16]. 
Therefore, even if vancomycin had been included in the 
empirical regimen, some of these deaths would still have been 
unavoidable. In addition, randomised studies of ceftazidime 
monotherapy [6, 7] and combination antibiotic therapy [2] 
have failed to demonstrate any survival advantage for patients 
treated with a glycopeptide antibiotic at the onset of fever.
The empirical use of vancomycin did not result in lower 
morbidity nor accelerate resolution of infection since the 
duration of fever was also comparable, whether or not patients 
were initially treated with the glycopeptide as has been 
reported in other studies [2* 6, 7]. Furthermore, the use of 
vancomycin is not without additional renal toxicity [2, 6].
Therapy was modified significantly later for those patients 
already treated empirically with vancomycin, as would be 
expected since vancomycin is the drug most commonly added 
to the initial regimen, but there was no difference in the 
average number of antimicrobials eventually employed. Also, 
once treatment with vancomycin has been started* instituting 
empirical antifungal therapy for persistent fever becomes more 
likely, reflecting the dwindling possibilities for further treat­
ment modifications rather than any increase in incidence of 
proven or suspected fungal infections [2].
It was also customary in the present study to add vancomy­
cin once a gram-positive organism was isolated, and, even 
more frequently, because of persistent fever. It might be 
argued that this was justified for infection involving coagulase- 
negative staphylococci since only half of the isolates proved to 
be susceptible to ceftazidime or the combination of piperacillin 
and tobramycin. However* half of these bacteria had already 
been eradicated by these regimens before vancomycin was 
added, indicating that the results of follow-up cultures were 
either not known at the time or ignored. Moreover* it has been 
demonstrated previously that adding a glycopeptide empiri­
cally is not only futile because it can be shown to be effective 
only for patients with microbiologically or clinically defined 
gram-positive infection [17], but it can also contribute to the 
emergence of vancomycin-resistant enterococci* particularly 
after prolonged treatment with the glycopeptide [10],
In conclusion* incorporating vancomycin in the initial 
empirical antibiotic regimen for febrile neutropenic patients 
does not appear necessary* even for skin and soft tissue infec­
tions associated with gram-positive bacteraemia. Rather* all 
the data suggest that empirical treatment with a glycopeptide 
is only essential in centres where methicillin-resistant Staphy­
lococcus aureus are a significant endemic problem and that 
vancomycin should only be added when there are clear, objec­
tive grounds for doing so. This necessitates daily clinical 
examination* relevant microbiological investigations and reg­
ular and timely review of the information gathered in order to 
a make a definitive diagnosis and employ the most suitable 
treatment. However, this demands no more than is considered 
good clinical practice and should help save unnecessary costs 
and keep adverse experiences to a minimum.
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